Treating acute coronary syndromes with new antiplatelet drugs: The mortality issue with prasugrel and ticagrelor

Current Medical Research and Opinion

Volumn 27, Issue 11, 2011, Pages 2117-2122

  De Servi, Stefano ^a   Navarese, Eliano Pio ^a   D'Urbano, Maurizio ^a   Savonitto, Stefano ^b  

^a Ospedale Civile di Legnano   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Acute coronary syndromes; Mortality; New antiplatelet drugs; Randomized studies

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; CAUSE OF DEATH; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; HEART DEATH; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; LIFE EXPECTANCY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RISK REDUCTION; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THORAX PAIN;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; CORONARY ANGIOGRAPHY; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2 RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 80054714519     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.618492     Document Type: Article

References (26)

1. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502 (Pubitemid 32758501)
2. Aradi D, Komócsi A, Vorobcsuk A, et al. Prognostic significance of high onclopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010;160:543-51
3. Navarese EP, Verdoia M, Schaffer A, et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM 2011; 104:561-9
4. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-73
5. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66
6. Wiviott SD, Braunwald E, McCabe CH, et al. for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)
7. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85
8. Wallentin L, Becker RC, Budaj A, et al. The PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
9. Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemostasis 2011;105:752-9
10. Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Thromb Haemostasis 2011;105:763-5
11. Serebruany VL. Mortality in the TRITON trial: update from the FDA prasugrel action package. Am J Cardiol 2010;105:1356-7
12. Montalescot G, Wiviott S, Braunwald E, et al. for the TRITON-TIMI 38 Investigators. Prasugrel compared to clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373:723-31
13. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122: 2131-41
14. Cannon CP, Harrington RA, James S, et al. PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93
15. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-84
16. Smith PK, Despotis GJ, Goodnough LT, et al. Mortality benefit with prasugrel in TRITON-TIMI 38 coronary artery bypass grafting (CABG) cohort: risk adjusted retrospective data analysis. Abstract 10881, presented at the AHA Scientific sessions 2010, Chicago, IL, November 2010
17. Marso SP, Bhatt DL, Roe MT, et al. For the PURSUIT Investigators. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation 2000;102:2952-8
18. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527
19. Chan MY, Becker RC, Harrington RA, et al. Noninvasive, medical management for non-ST-elevation acute coronary syndromes. Am Heart J 2008; 155:397-407
20. Alexander D, Ou FS, Roe MT, et al. American College of Cardiology/American Heart Association. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Am Heart J 2008;156:606-12
21. Chan MY, Mahaffey KW, Sun LJ, et al. Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. JACC Cardiovasc Interv 2008;1:369-78.
22. Chin CT, Roe MT, Fox KA, et al. Design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY managed Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010;160:16-22
23. Wiviott SD, Antman EM, Braunwald E. Mortality in the TRITON trial: update from the FDA prasugrel action package. Am J Cardiol 2010;106:293-4
24. De Servi S, Savonitto S. How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial? Int J Cardiol 2011;149:265-7
25. Ruff CT, Giugliano RP, Antman EM, et al. For the TRITON-TIMI 38 Investigators. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol 2010, in press, available on line [Last accessed 19 November 2010]
26. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2011;124:544-54